What is BIO ESSENCE CORP's earnings per share (EPS)?

BIO ESSENCE CORP (BIOE) reported diluted earnings per share of $0.02 for fiscal year 2025. This represents a 166.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BIO ESSENCE CORP (BIOE) Financials

BIOE

Trailing 12 months to June 30, 2026

Revenue $2.9M YoY not available

Net Income $1.5M YoY not available

EPS (Diluted) $0.02 +150.0% YoY

Operating Cash Flow $1.1M +16.7% YoY

Market Cap $16.1M as of Oct 13, 2026

Price / Sales 5.5x on $2.9M revenue, trailing 12 months to June 30, 2026

Price / Earnings 10.6x on $1.5M net income, trailing 12 months to June 30, 2026

Price / Book 6.9x on $2.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIOE SEC filings page.

BIO ESSENCE CORP (BIOE) reported $2.9M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BIOE FY2025 2026-10-03

A sharp 2025 sales rebound turned years of losses into reported profit, but liabilities still overwhelm the company’s small asset base.

Operating cash flow was $624K in FY2024 despite a net loss, then reached $1.6M in FY2025. That shift alongside the move to reported profitability suggests the 2025 result was accompanied by cash generation, though the unusual cash-to-profit gap points to working-capital or other operating adjustments.

Gross margin expansion accelerated from 50.3% in FY2023 to 75.3% in FY2025, indicating the sales mix or unit economics changed materially. SG&A fell from $677K in FY2024 to $498K in FY2025, so lower overhead relative to sales also helped convert the rebound into operating profit.

Despite reported 2025 profit, equity remained negative at -$2.1M, meaning accumulated deficits still outweigh the company’s recorded net assets. Liabilities of $2.5M exceeded assets of $422K, while a 0.2x current ratio shows near-term obligations were much larger than current resources.

Financial Health Signals

Financial health score not available

BIO ESSENCE CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-21.98

BIO ESSENCE CORP scores -21.98, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($16.1M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

9/9

BIO ESSENCE CORP passes 9 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.75x

For every $1 of reported earnings, BIO ESSENCE CORP generates $1.75 in operating cash flow ($1.6M OCF vs $896K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

411.72x

BIO ESSENCE CORP earns $411.72 in operating income for every $1 of interest expense ($900K vs $2K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$795K

YoY+206.7%

QoQ+58.8%

BIO ESSENCE CORP generated $795K in revenue in Q2 2026. This represents an increase of 206.7% from the same quarter a year earlier. Against the prior quarter it is up 58.8%.

EBITDA

$383K

YoY+524.8%

QoQ+77.4%

BIO ESSENCE CORP's EBITDA was $383K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 524.8% from the same quarter a year earlier. Against the prior quarter it is up 77.4%.

Net Income

$270K

YoY+351.2%

QoQ+31.5%

BIO ESSENCE CORP reported $270K in net income in Q2 2026. This represents an increase of 351.2% from the same quarter a year earlier. Against the prior quarter it is up 31.5%.

EPS (Diluted)

$0.00

BIO ESSENCE CORP earned $0.00 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$675

QoQ-98.1%

BIO ESSENCE CORP held $675 in cash against $57K in long-term debt as of Q2 2026, with $1.6M of liabilities due within a year.

Shares Outstanding

54M

YoY+41.6%

QoQ+15.0%

5Y CAGR+10.3%

BIO ESSENCE CORP had 54M shares outstanding in Q2 2026. This represents an increase of 41.6% from the same quarter a year earlier. Against the prior quarter it is up 15.0%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

59.2%

YoY-5.9pp

QoQ-4.6pp

BIO ESSENCE CORP's gross margin was 59.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.6 percentage points.

Operating Margin

35.1%

YoY+11.5pp

QoQ-8.0pp

BIO ESSENCE CORP's operating margin was 35.1% in Q2 2026, reflecting core business profitability. This is up 11.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 8.0 percentage points.

Net Margin

34.0%

YoY+10.9pp

QoQ-7.1pp

BIO ESSENCE CORP's net profit margin was 34.0% in Q2 2026, showing the share of revenue converted to profit. This is up 10.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.1 percentage points.

Return on Equity

11.5%

BIO ESSENCE CORP's ROE was 11.5% in Q2 2026, measuring profit generated per dollar of shareholder equity.

Capital Allocation

None of these metrics is reported for Q2 2026.

BIOE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIOE quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	$2.9M	$1.9M+485.8%	$324K-41.3%	$552K-11.3%	$622K-30.0%	$888K-7.4%	$959K
Cost of Revenue	$883K	$469K+339.0%	$107K-61.0%	$274K-6.5%	$293K+219.6%	$92K-87.5%	$731K
Gross Profit	$2.0M	$1.4M+558.0%	$217K-21.8%	$277K-15.5%	$328K+10.1%	$298K+31.3%	$227K
SG&A Expenses	$459K	$498K-26.4%	$677K+95.8%	$346K-54.7%	$763K-29.1%	$1.1M+18.6%	$908K
Operating Income	$1.5M	$900K+295.9%	-$459K-32.9%	-$346K+32.4%	-$511K+40.4%	-$858K-3.0%	-$833K
EBITDA	N/A	$900K+296.3%	-$459K-34.5%	-$341K+31.4%	-$497K+39.6%	-$822K-2.8%	-$799K
Interest Expense	-$704	$2K+1.5%	$2K-87.6%	$17K+22.7%	$14K-63.4%	$39K-8.0%	$42K
Income Tax	N/A	$8000.0%	$800-50.0%	$2K-36.0%	$3K-24.2%	$3K0.0%	$3K
Net Income	$1.5M	$896K+168.5%	-$1.3M-34.7%	-$972K-20.0%	-$810K-25.0%	-$648K-8.7%	-$596K
EPS (Basic)	N/A	$0.02+166.7%	-$0.030.0%	-$0.03-50.0%	-$0.020.0%	-$0.02	N/A
EPS (Diluted)	$0.02	$0.02+166.7%	-$0.030.0%	-$0.03-50.0%	-$0.020.0%	-$0.02	N/A
Diluted Shares (Avg)	N/A	38M0.0%	38M+5.7%	36M+8.9%	33M0.0%	33M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$795K+206.7%	$501K+2155.8%	$1.5M	$137K+1.6%	$259K+521.5%	$22K	N/A	$135K-13.5%
Cost of Revenue	$324K+258.6%	$181K+11216.9%	$336K	$41K-23.6%	$90K+623.4%	$2K	N/A	$54K-60.4%
Gross Profit	$470K+178.8%	$319K+1451.2%	$1.1M	$96K+18.2%	$169K+477.8%	$21K	N/A	$81K+300.1%
SG&A Expenses	$191K+77.8%	$103K-54.3%	$84K	$81K-64.4%	$107K-44.7%	$225K+48.3%	N/A	$227K+175.2%
Operating Income	$279K+356.2%	$216K+205.2%	$1.0M	$14K+109.7%	$61K+137.1%	-$205K-35.1%	N/A	-$146K-77.2%
EBITDA	$383K+524.8%	$216K+205.3%	$1.0M	$14K+109.8%	$61K+137.2%	-$205K-35.5%	N/A	-$146K-90.3%
Interest Expense	-$2K-528.2%	$542-0.2%	$540	$556+3.7%	$547+1.5%	$543+0.2%	N/A	$536-2.2%
Income Tax	$10K+1201.4%	$10K	N/A	N/A	$8000.0%	N/A	N/A	N/A
Net Income	$270K+351.2%	$205K+199.8%	$1.0M	$13K+101.1%	$60K+127.8%	-$206K-253.6%	N/A	-$1.2M-281.0%
EPS (Basic)	$0.00	$0.00+100.0%	$0.02	$0.00+100.0%	$0.00+100.0%	-$0.01	$0.00+100.0%	-$0.03-200.0%
EPS (Diluted)	$0.00	$0.00+100.0%	$0.02	$0.00+100.0%	$0.00+100.0%	-$0.01	$0.00+100.0%	-$0.03-200.0%

Not reported in any period shown, so not listed: R&D Expenses, Diluted Shares (Avg).

BIOE Balance Sheet

BIOE quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$422K+50.3%	$281K-89.8%	$2.8M+78.2%	$1.5M-8.9%	$1.7M-7.9%	$1.8M
Current Assets	$422K+50.5%	$281K-6.4%	$300K+47.2%	$204K-22.2%	$262K-20.5%	$330K
Cash & Equivalents	N/A	$1K+1102.6%	$114-98.2%	$6K+1966.7%	$303-94.3%	$5K
Short-Term Investments	N/A	$0	$0	$0	$0	$0
Inventory	N/A	N/A	$143K-20.9%	$181K-14.9%	$213K-21.8%	$272K
Accounts Receivable	$23K+357.7%	$5K-85.4%	$35K+526.8%	$6K-66.7%	$17K-62.7%	$45K
Long-Term Investments	N/A	$0	$0	$0	$0	$0
Total Liabilities	$2.5M-23.2%	$3.3M-26.4%	$4.4M-7.7%	$4.8M+15.9%	$4.1M+13.8%	$3.6M
Current Liabilities	$2.4M-13.0%	$2.8M+14.4%	$2.5M-31.1%	$3.6M+29.1%	$2.8M+45.4%	$1.9M
Non-Current Liabilities	$56K-87.4%	$447K-60.7%	$1.1M-7.2%	$1.2M-10.5%	$1.4M-20.8%	$1.7M
Long-Term Debt	$57K+1.8%	$56K	N/A	N/A	N/A	N/A
Total Equity	-$2.1M+30.2%	-$3.0M-78.8%	-$1.7M+48.7%	-$3.2M-33.3%	-$2.4M-36.4%	-$1.8M
Retained Earnings	-$9.6M+8.6%	-$10.4M-14.3%	-$9.1M-11.9%	-$8.2M-11.0%	-$7.4M-9.6%	-$6.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$4.0M+3452.1%	$789K+115.7%	$422K+50.3%	$185K-74.2%	$113K-94.6%	$366K-83.8%	$281K-89.8%	$716K-65.1%
Current Assets	$607K+439.2%	$789K+115.9%	$422K+50.5%	$184K-74.2%	$112K-87.7%	$365K-59.3%	$281K-6.4%	$716K+212.1%
Cash & Equivalents	$675	$36K	N/A	$29K-3.6%	N/A	N/A	$1K+1102.6%	$30K+33403.4%
Short-Term Investments	$0	$0	N/A	$0	N/A	N/A	$0	$0
Accounts Receivable	N/A	$5K-35.1%	$23K+357.7%	$5K-92.4%	$5K-37.0%	$8K	$5K-85.4%	$65K+398.8%
Long-Term Investments	$0	$0	N/A	$0	N/A	N/A	$0	$0
Total Liabilities	$1.7M-48.6%	$2.2M-37.4%	$2.5M-23.2%	$3.3M-10.1%	$3.2M-15.9%	$3.5M-6.4%	$3.3M-26.4%	$3.7M+4.0%
Current Liabilities	$1.6M-47.7%	$2.2M-33.3%	$2.4M-13.0%	$3.2M+5.3%	$3.1M-1.2%	$3.2M+11.0%	$2.8M+14.4%	$3.1M+39.8%
Non-Current Liabilities	$55K-64.6%	$56K-81.6%	$56K-87.4%	$56K-90.4%	$156K-78.5%	$302K-65.0%	$447K-60.7%	$591K-55.3%
Long-Term Debt	$57K-2.2%	$57K+1.8%	$57K+1.8%	$58K+1.8%	$58K	$56K	$56K	$57K
Total Equity	$2.3M+175.2%	-$1.4M+55.0%	-$2.1M+30.2%	-$3.1M-5.5%	-$3.1M-78.8%	-$3.2M-108.0%	-$3.0M-78.8%	-$2.9M-100.6%
Retained Earnings	-$9.1M+14.3%	-$9.3M+12.3%	-$9.6M+8.6%	-$10.6M-1.5%	-$10.6M-14.9%	-$10.7M-18.3%	-$10.4M-14.3%	-$10.4M-16.5%

Not reported in any period shown, so not listed: Inventory, Goodwill.

BIOE Cash Flow Statement

BIOE quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	$1.1M	$1.6M+151.6%	$624K+160.8%	-$1.0M-45.8%	-$703K+45.7%	-$1.3M-76.6%	-$733K
Depreciation & Amortization	N/A	$235-74.2%	$911-81.0%	$5K-67.0%	$15K-59.5%	$36K+7.6%	$33K
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	N/A	$9K
Capital Expenditures	N/A	N/A	N/A	$4K-3.4%	$4K-96.9%	$119K+1522.5%	$7K
Free Cash Flow	N/A	N/A	N/A	-$1.0M-45.6%	-$707K+50.0%	-$1.4M-91.0%	-$740K
Investing Cash Flow	N/A	N/A	-$114+99.9%	-$91K-54.7%	-$59K+49.4%	-$117K-1485.8%	-$7K
Financing Cash Flow	-$990K	-$1.6M-152.4%	-$622K-156.0%	$1.1M+44.6%	$768K-45.3%	$1.4M+92.8%	$729K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$60K-64.5%	-$412K-1480.3%	$1.2M+193.3%	$187K-47.6%	$168K+998.7%	-$26K+84.8%	$423K+307.3%	$357K+203.6%
Depreciation & Amortization	$104K+175493.2%	$590.0%	$59+1.7%	$58-1.7%	$59-80.1%	$59-88.1%	$58+102.4%	$59-99.0%
Financing Cash Flow	-$10K+93.8%	$448K+1714.5%	-$1.3M-181.2%	-$158K+53.0%	-$168K-2789.6%	$25K-85.6%	-$452K-254.6%	-$337K-196.8%

Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BIOE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BIOE quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	75.3%+8.3pp	67.0%+16.7pp	50.3%-2.5pp	52.8%+19.2pp	33.6%+9.9pp	23.7%
Operating Margin	47.4%	-141.8%	-62.7%+19.6pp	-82.2%+14.3pp	-96.6%-9.7pp	-86.8%
Net Margin	47.2%	-404.0%	-176.2%	-130.3%	-72.9%-10.8pp	-62.2%
Return on Assets	212.1%+677.8pp	-465.7%-430.5pp	-35.2%+17.1pp	-52.3%-14.2pp	-38.1%-5.8pp	-32.3%
Current Ratio	0.17+0.1x	0.100.0x	0.12+0.1x	0.060.0x	0.10-0.1x	0.17
Asset Turnover	4.49+3.3x	1.15+1.0x	0.20-0.2x	0.40-0.1x	0.520.0x	0.52
FCF Margin	N/A	N/A	-186.6%	-113.7%	-159.2%	-77.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	59.2%-5.9pp	63.8%-29.0pp	77.3%	70.0%+9.9pp	65.1%-4.9pp	92.8%	N/A	60.1%+47.1pp
Operating Margin	35.1%+11.5pp	43.1%	69.6%	10.4%	23.6%	-924.3%	N/A	-108.7%
Net Margin	34.0%+10.9pp	41.0%	69.6%	9.5%	23.1%	-927.3%	N/A	-890.6%
Return on Equity	11.5%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	6.8%-46.4pp	26.0%+82.3pp	243.6%	7.0%+174.6pp	53.1%+63.4pp	-56.3%-62.2pp	N/A	-167.5%-152.2pp
Current Ratio	0.38+0.3x	0.37+0.3x	0.17+0.1x	0.06-0.2x	0.04-0.3x	0.11-0.2x	0.100.0x	0.23+0.1x
Debt-to-Equity	0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.20-2.1x	0.63+0.6x	3.50	0.74+0.6x	2.30+2.3x	0.06	N/A	0.19+0.1x

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$2.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Where BIO ESSENCE CORP Ranks

Frequently Asked Questions

What is BIO ESSENCE CORP's annual revenue?

BIO ESSENCE CORP (BIOE) reported $1.9M in total revenue for fiscal year 2025. This represents a 485.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BIO ESSENCE CORP's revenue growing?

BIO ESSENCE CORP (BIOE) revenue grew by 485.8% year-over-year, from $324K to $1.9M in fiscal year 2025.

Is BIO ESSENCE CORP profitable?

Yes, BIO ESSENCE CORP (BIOE) reported a net income of $896K in fiscal year 2025, with a net profit margin of 47.2%.

What is BIO ESSENCE CORP's EBITDA?

BIO ESSENCE CORP (BIOE) had EBITDA of $900K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is BIO ESSENCE CORP's gross margin?

BIO ESSENCE CORP (BIOE) had a gross margin of 75.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BIO ESSENCE CORP's operating margin?

BIO ESSENCE CORP (BIOE) had an operating margin of 47.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BIO ESSENCE CORP's net profit margin?

BIO ESSENCE CORP (BIOE) had a net profit margin of 47.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BIO ESSENCE CORP's operating cash flow?

BIO ESSENCE CORP (BIOE) generated $1.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BIO ESSENCE CORP's total assets?

BIO ESSENCE CORP (BIOE) had $422K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does BIO ESSENCE CORP have outstanding?

BIO ESSENCE CORP (BIOE) had 38M shares outstanding as of fiscal year 2025.

What is BIO ESSENCE CORP's current ratio?

BIO ESSENCE CORP (BIOE) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is BIO ESSENCE CORP's return on assets (ROA)?

BIO ESSENCE CORP (BIOE) had a return on assets of 212.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BIO ESSENCE CORP's P/E ratio?

BIO ESSENCE CORP (BIOE) trades at 10.6x earnings, its market capitalization divided by net income of $1.5M net income, trailing 12 months to June 30, 2026. The market capitalization is $16.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is BIO ESSENCE CORP's price-to-sales ratio?

BIO ESSENCE CORP (BIOE) trades at 5.5x sales, its market capitalization divided by revenue of $2.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $16.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is BIO ESSENCE CORP's debt-to-equity ratio negative or not reported?

BIO ESSENCE CORP (BIOE) has negative shareholder equity of -$2.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is BIO ESSENCE CORP's Altman Z-Score?

BIO ESSENCE CORP (BIOE) has an Altman Z-Score of -21.98, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BIO ESSENCE CORP's Piotroski F-Score?

BIO ESSENCE CORP (BIOE) has a Piotroski F-Score of 9 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BIO ESSENCE CORP's earnings high quality?

BIO ESSENCE CORP (BIOE) has an earnings quality ratio of 1.75x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BIO ESSENCE CORP cover its interest payments?

BIO ESSENCE CORP (BIOE) has an interest coverage ratio of 411.72x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.